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ABSTRACT OF THE DISSERTATION
A Novel Exo-Proteomic Approach to the Study of Traumatic Brain Injury
by
Ron B. Moyron
Doctor of Philosophy, Graduate Program in Biochemistry
Loma Linda University, September 2018
Dr. Nathan R. Wall, Chairperson

Concussions and Traumatic Brain Injuries (TBI) are significant health concerns
and affect a wide cross section of society. Current diagnostic criteria and modalities, such
as brain imaging and subjective measures of consciousness such as the Glasgow Coma
Scale (GCS) score, are insufficient to properly diagnose the full spectrum of head
injuries. Assessment of injury severity and outcome are further complicated by the vast
array of symptoms, many of which mimic those displayed by other disorders. It is
important to possess a better diagnostic tool for head injury triage and outcome
prediction. One current line of inquiry seeks to discover a “traumatic brain injury
biomarker”, or a number of them, in order to differentiate the healthy patient from the
concussed individual. However, there are challenges in proteomic analysis of neuronal
proteins. Current methods, such as sampling cerebral spinal fluid via lumbar puncture,
are both invasive and carry risk of injury. Discovery of trauma-specific biomarkers
present in peripheral blood may present a viable alternative. However, the likely
degradation of neuronal proteins in the peripheral circulation is an obstacle. Exosomes,
small membrane vesicles known to carry proteins and injury-specific biomarkers, may
help provide an ideal modality for the study of the TBI. The current work sought to

xii

assess the utility of an exo-proteomic approach for the study of traumatic brain injury.
Blood samples taken from trauma patients admitted to a Level 1 Trauma Center were
stratified according to GCS score and their exo-proteomic content was analyzed via mass
spectrometry. Results indicated differential exosomal protein expression in patients
corresponding to injury severity, as categorized by GCS score. Based on these findings,
we believe that exo-proteomic analysis of patients with differing level of injury severity
lends itself well to the discovery of potential trauma-specific biomarkers that can aid in
the establishment of a true differential diagnostic for the full spectrum of concussion and
traumatic brain injuries.
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In the early portion of the 21st Century, after decades of neglect and an almost
complete lack of concern, concussions and head trauma (and their aftermath) have come
to dominate the public consciousness. With the conflicts in Afghanistan and Iraq, and the
alarming injury rates and subsequent deaths linked to contact sports, particularly
American football, the onus has been placed on researchers to discover new and novel
ways to address this significant and growing problem. There are estimates that every 21
seconds in the United States someone sustains a traumatic brain injury (TBI) with 50,000
attributable deaths each year. These numbers account for one-third of all injury-related
deaths in the U.S. and more than 1 million people seeking medical care for TBI annually.
More than 5 million Americans are living with TBI-related disabilities and the United
States spends an estimated $56 billion per year treating the after-effects of this condition1.
TBI can result from a multitude of causes, the most common being motor vehicle
accidents, falls and/or assaults, exposure to explosions (i.e. soldiers serving in combat)
and penetrating head trauma (gunshot wounds etc.). The terms mild TBI (mTBI) and
concussion have often been used interchangeably and the traditional, societal perception
of these injuries has been that they are insipid, or even inconsequential in nature.
However, our growing body of knowledge is beginning to paint a very different, and
decidedly starker, picture. TBI, even of the mTBI variety, can cause significant damage
to both white matter and axons 2 and repeated episodes of mTBI and/or subconcussive
trauma can induce significant worsening of clinical symptoms that strongly resemble
both Parkinson’s and Alzheimer’s disease among others.
Severe TBI tend to be more straightforward than less severe forms such as mTBI.
These less severe injuries have confounded accurate, concise definition and are incredibly
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difficult to diagnose. Clinicians and researchers have struggled to agree on a single,
standard definition of mTBI. This is most likely due to the vast amount of diversity and
lack of specificity in symptomology. All-too-often, those who have suffered an acute
mTBI present with symptoms that mimic a variety of other conditions, some even
psychological in nature. This heterogeneity in symptomology and the fact that many
patients with mTBI have symptoms that closely mimic other disorders make many
mTBIs almost impossible to accurately detect. Most mTBI patients recover well and do
not suffer from lingering symptoms. However, many who have suffered an mTBI
experience worsening symptoms that continue to progress and become more severe
manifestations of emotional, psychological and physical trauma. Estimates are that 15%
of patients with mTBI develop persistent cognitive dysfunction 2. Currently, the
American Congress of Rehabilitation Medicine defines an mTBI as, a traumatically
induced physiological disruption of brain function, as manifested by at least one of the
following: loss of consciousness, any loss of memory for events immediately before or
after the event, focal neurologic deficit that may or may not be transient, but where the
severity of the injury does not exceed a loss of consciousness of approximately 30 min or
less, an initial Glasgow Coma Scale (GCS) score of 13–15 and post-traumatic amnesia
not greater than 24 h 3.
Concussions and mTBI have been called a “silent epidemic” 4 as both
concussions and subconcussive events are often undiagnosed or unreported altogether.
Mild traumatic brain injuries are also alarmingly common. It has been estimated that
more than 1.5 million Americans sustain mTBI without a subsequent loss of
consciousness and without the need for hospitalization. An equal or greater number
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sustain an injury that impairs consciousness but is not severe enough to require long-term
hospitalization. Mild Traumatic brain injury affects up to 10 million people globally and
accounts for 70-90% of all TBI cases 3.
Blasts, vehicle crashes, and other mechanisms place soldiers, athletes and us all at
risk for TBI. A mild TBI or mTBI is characterized by mechanical injury to the head with
brief loss of consciousness or altered mental status 5. Surveys of soldiers who have
recently returned from active duty indicate that up to 16% reported that a loss of
consciousness was associated with their injuries 6. Soldiers with TBI, particularly those
who had lost consciousness with their injury are more likely to meet criteria for
posttraumatic stress disorder (PTSD) and major depression and poor general health.
They also report more lost workdays, medical visits and a higher number of
postconcussive symptoms than do soldiers that experienced other types of injuries 5, 6.
Athletes suffer repetitive concussive and subconcussive brain trauma as well, and as a
result they suffer executive dysfunction, memory impairment, depression and suicidality,
apathy, poor impulse control, and eventually dementia 7. It is important to note that most
individuals with mTBI recover within 3-6 months of the injury. However, a subset will
develop persistent neuropsychiatric symptoms 8, 9. Unfortunately, most individuals with
mTBI do not seek out and thus do not receive rehabilitation and thus many become
permanently disabled 5. Although it is difficult to detect an mTBI simply using a clinical
examination, there are studies now which suggest that early identification and treatment
of the symptoms can improve outcomes 10, 11. It is therefore imperative to devote effort to
the identification of novel biomarkers that will enhance early TBI detection, management
and therapeutic response that could be tailored to the soldiers, athletes or the community.
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Important to mTBI diagnosis and management is to determine an optimal combination of
clinical indicators or biomarkers that could detect injury early with both high specificity
and sensitivity and with limited invasiveness. In spite of the availability of a number of
gene products considered as promising biomarkers (S100B and neuron specific enolase
(NSE)), it is recognized that their combined use with the available clinical information is
still insufficient for early diagnosis and for guiding individualized therapeutic
interventions and predicting outcomes 12. However, there is growing interest in using
proteomic approaches to identify serum autoantibodies recognizing trauma-associated
antigens (TrAA), as well as serum microvesicles called exosomes and their content, as
serological biomarkers 13-19. This interest stems from the notion that these blood
components are considered “sensors” of molecular events associated with pathology 16, 20,
21

.
In addition to clinical variables available at the time of injury, the potential utility

of quantifying serum biomarkers of structural damage or as mediators of cellular,
biochemical, or molecular secondary injury cascades for predicting outcome after TBI
has been investigated 4, 22. S100B is a calcium-binding protein found in glial cells,
predominantly astrocytes, and at physiologic concentrations has been shown to provide
both neurotrophic and neuroprotective effects. Elevated presence of S100B in peripheral
blood and/or cerebral spinal fluid (CSF) may indicate neuronal damage and possible
blood brain barrier disruption 23. In acute TBI and post-acute scenarios, S100B has been
documented to be elevated and as a result may lack specificity, better serving as a marker
for polytrauma. NSE is a glycolytic enzyme that catalyzes the conversion of 2phosphoglycerate to phosphoenolpyruvate (PEP). The neuron specific isomer of enolase
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is found primarily in neuron cytoplasm. In TBI patients, NSE may indicate neuronal
damage as NSE has been reported elevated in patients with mTBI. However, NSE lacks
sensitivity and specificity with its levels shown to be elevated in non-trauma patients due
to a variety of causes 24. Additionally, an increased NSE level can result from hemolysis,
a common occurrence in trauma cases. There is also a poor correlation between NSE
serum levels and Glasgow Outcome Scale (a longer term evaluative measure when
compared with GCS) 25.
Together, S100B and NSE have been shown to be sensitive to cranial pathology
after mTBI with strong negative predictive values 5. In addition, elevated levels of these
biomarkers have been linked to poor predictive outcomes up to 12 months post injury.
Testing these biomarkers has not been adopted clinically because of their low levels,
specificity and reports that non-cranial injuries also contribute to elevations in these two
markers 26. It is therefore imperative that proteome-profiling & immunoseroproteomics
approaches, currently considered the most promising strategy for the identification of
serum biomarkers 13, 14, 16, 17 be adapted and applied to TBI and mTBI. The application of
such approaches in the context of soldiers, athletes or the general population has never
been done before.
The list of potential biomarkers for TBI, though small, continues to grow with the
top investigated targets, besides S100B and NSE, being Glial Fibrillary Acidic Protein
(GFAP), Myelin Basic Protein (MBP), and Ubiquitin C-terminal Hydrolase-L1 (UCHL1) 27. GFAP is an intermediate filament protein, encoded by the GFAP gene, that is
expressed in many cell types in the CNS, most particularly glial cells but also astrocytes
and ependymal cells 28. GFAP is a major component of the astrocyte cytoskeleton which
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is acutely elevated following mTBI 29, 30. Presence of GFAP in CSF and peripheral blood
in trauma patients may suggest astrocyte damage and possible blood brain barrier (BBB)
disruption 31. GFAP seems to have both high sensitivity and specificity but has not yet
been shown to correlate with longer-term disruption. MBP, found in myelin and known
to play a key role in myelination, is one of the most abundant CNS proteins 32. MBP
levels are elevated in trauma patients post TBI 33. Higher MBP levels may suggest axonal
injury and damage and may be related to poor outcome in trauma patients 34. Detection of
aberrant levels of serum MBP may take 48-72 hours and may be somewhat impractical
for diagnostic purposes at this point. Cleaved tau (C-tau), a microtubule associated
protein that is expressed in CNS axons, has been recorded post TBI 35. A presence of Ctau in plasma may suggest hyperphosphorylation and formation of neurofibrillary tangles
that have been seen in post mortem samples of patients with chronic traumatic
encephalopathy (CTE) 36. Although C-tau has been correlated with TBI, to date its
presence was not indicative of intracranial lesions on CT scans of patients with head
trauma. Furthermore, C-tau has not been proven to be an accurate predictor of post
concussive syndrome (PCS) and longer-term recovery 36, 37. UCH-L1 is a
deubiquitinating enzyme found in the cytoplasm of interneurons and is the newest
proposed biomarker in TBI. Its presence may suggest neuronal damage and BBB
disruption as its presence is abundant in neurons 38. UCH-L1 is also known in the neuron
literature as neuronal-specific protein gene product (PGP 9.3) and in studies performed in
CSF, an inverse relationship exists as its presence increased as GCS decreased. This
relationship indicates a direct association between UCH-L1 and trauma levels 38.
However, to date, little is known about UCH-L1 levels in trauma patients 27, 37, 39 making
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UCH-L1 a very promising target in TBI studies. Produced by calpain and caspase 3
alpha 2, spectrin breakdown products (SBDP) are found in presynaptic terminals and
axons 37. SBDP presence in trauma patients, especially those with subarachnoid
hemorrhage (SAH) may suggest cellular necrosis following brain injury 40. Along with
UCH-L1, SBDPs are promising proteins for head trauma analysis.
Despite the recent increase in interest and funding in the study of head trauma, the
field is in its infancy. There are currently no widely accepted clinical biomarkers known
to be indicative of head trauma. In spite of the availability of a number of gene products
considered as promising biomarkers (described above), it is recognized that their
combined use with the available clinical information is still insufficient for early
diagnosis and for guiding individualized therapeutic interventions and predicting
outcomes 12. Much has been made of the urgent need to discover a novel diagnostic tool
in order to alleviate the high costs of radiologic testing and expedite the treatment
process. Compounding the difficulty in the diagnosis of concussion and the more mild
forms of TBI, where there may exist no findings on a CT scan, is the fact that the etiology
of the continuum from concussion to PCS to CTE is a mystery. What allows one trauma
patient with a concussion or head injury to recover quickly and be largely asymptomatic
while another, with similar acute presentation, may suffer long term or permanent
disability is unknown. We are only just beginning to understand the most severe end of
the head trauma spectrum, the CTE exhibited by retired boxers and American football
players. But we do not yet understand all of the factors that lead from one, or multiple,
concussive events to the tragic disabilities exhibited by some of our greatest icons like
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Muhammad Ali and the brave men and women who served our country in the Armed
services.
Rather than finding one single novel traumatic biomarker, the proverbial “magic
bullet”, it is quite possible that the beginnings of an answer may lie in the adoption, or
formalization, of a panel of trauma-specific proteins. It may be possible to combine one
or more of the aforementioned proteins, along with yet undiscovered biomarkers, and
integrate them with post injury assessment and therapy to stem the tide of this
increasingly frightening epidemic.
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Abstract
Traumatic Brain Injuries (TBI) are among the most misdiagnosed and
underreported types of head trauma. The potential long-term impact of undiagnosed or
incorrectly identified concussions and other head injuries are potentially devastating, as
evidenced by the increasing societal burden exhibited by soldiers returning from combat
and athletes in contact sports. Concussions and TBI are notoriously difficult to correctly
diagnose and prognosis for these injuries is poorly understood. In order to increase the
likelihood of successful diagnosis, treatment, and prediction of outcomes, a definitive
differential diagnosis will need to be established. The establishment of a “trauma–specific
profile” or a panel of known trauma markers will significantly aid in this goal. Small
membrane vesicles called exosomes have been shown to contain proteins and injuryspecific biomarkers. In the future it is possible that they could become an important tool,
utilized for their diagnostic and therapeutic potential.

15

Significance of the Study
Research is increasingly focusing on the triage and assessment of all manner of
Traumatic Brain Injuries (TBI). The inherent difficulty in the differential diagnosis of
head traumas is well understood as the heterogeneity of symptomatic presentation, the
significant number of unreported injuries, and the disparate etiologies inherent in the
injuries greatly increase the risk for misdiagnosis. Most current proteomic approaches
focus on assessing the small number of currently known markers of neuronal injury either
individually or, at most, in pairs. In addition, many studies focus on detection of the
presence of these few markers in cerebral spinal fluid (CSF). These approaches, while
valid, present significant clinical challenges as the difficulty of CSF sample collection,
and its inherent dangers, are well known. Discovery of trauma-specific biomarkers that
might be present in a peripheral blood sample could serve as a de-facto “liquid biopsy”
for concussion or TBI could greatly aid clinicians in proper differential diagnosis and
assessment of head injury. However, the likelihood of the degradation of most neuronal
proteins in the peripheral blood presents significant challenges. An exo-proteomic
approach lends itself well to an examination of injury-specific proteins that otherwise
might not be present in peripheral blood at the realistic time frame of injury assessment
and triage.

Introduction
Concussions and mild Traumatic Brain Injuries (mTBI) are garnering greater
recognition and focus due to their widespread impact. According to estimates from the
Centers for Disease Control and Prevention (CDC), approximately 1.7 million Americans
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sustain TBI every year. TBI also contributes to about a third of all injury-related deaths,
resulting in over 52,000 deaths a year 1. Perhaps more alarming are estimates that those
people with TBI who do not seek treatment account for a quarter of all those who sustain
a TBI in the United States 1. Classification of TBI (mild, moderate, or severe) is based
upon a patient’s responsiveness as described by their score on the Glasgow Comma Scale
(GCS): some authors stratify according to the following criteria, persons with GCS scores
of 3–8 are classified with a severe TBI, those with scores of 9–12 are classified with a
moderate TBI, and those with scores of 13–15 are classified with a mild TBI 2. However,
the modern applicability of these gradations is debatable as the schema was developed
over 40 years ago 3. TBI can result from a wide variety of causes including (but not
limited to): motor vehicle collisions, blast-induced injury, falls, gunshot wounds, assaults,
and other penetrating trauma. TBI has traditionally been viewed as a single, transitory
event with limited, episodic effect. However, due to its vast heterogeneity of symptom
presentation and lengthy duration of dysfunction, TBI is now being viewed as a disease
with significant potential for devastating long-term impact 4-8. Mild traumatic brain
injuries are also alarmingly common. It has been estimated that more than 1.5 million
Americans sustain mTBI without a subsequent loss of consciousness and without the
need for hospitalization. An equal or greater number sustain an injury that impairs
consciousness but is not severe enough to require long- term hospitalization. Mild
Traumatic brain injury affects up to 10 million people globally and accounts for 70-90%
of all TBI cases 3. Concussions and mTBI have been called a “silent epidemic” 4 as both
concussions and sub concussive events are often undiagnosed or unreported altogether.
Evidence is increasing that a crucial means of cell-cell and cell-extracellular
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communication within the microenvironment that makes up the site of trauma is through
the release and uptake of small extracellular vesicles (EVs) called exosomes. Exosomes
contain a subset of the originating cells proteins and RNAs 9, but compared to their cells
of origin, these exosome are more stable and can cross the blood brain barrier 10.
Exosomes contain on the surface of their membranes, proteins that act to present antigen
to immune cells and produce various cell signals to recipient cells, either surrounding or
distal, resulting in the interaction and deposition of the biomaterials they contain11. In
this study we identified exosomal protein contents from the plasma of GCS-stratified
patients in order to identify an injury severity specific marker. Future studies of these
markers may aid in the treatment decisions and severity monitoring for individuals
having suffered a possible head trauma.
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Experimental Methods
Patient Samples
A total of 78 patients were included for this study. Any patient admitted to the
Emergency Department of our Level 1 Trauma Center as a result of generalized trauma
was considered eligible for admission to this study. Common mechanisms of injury
included (but were not limited to): auto and motorcycle accidents, auto vs. pedestrian
incidents, falls, assaults, knife injuries, and gunshot wounds. Participants were selected
by the Acute Care Surgery service, and peripheral blood samples were taken at
admission, and at 24 and 48-hour intervals. Patients were stratified according to GCS and
placed in the following categories: No significant injury (GCS:15; n= 36), Mild to
Moderate Injury (GCS: 9-14; n= 17), and Severe Injury (GCS: 3-8; n= 25). Our original
categorization schema stratified patients in four GCS categories (GCS:15, No Significant
Injury; GCS:13-14, Mild Injury; GCS:9-12, Moderate Injury; and GCS:3-8, Severe
Injury) rather than the three listed (A, B/C, and D). However, due to an extremely limited
number of available patient samples in the Moderate Injury (GCS:9-12) classification, it
was decided that the best way to approach sample analysis was to aggregate Groups B
(GCS:13,14) and C (GCS: 9-12) and therefore the group entitled B/C was formed. For the
purposes of our analysis we designated the GCS assessed at 0 hour as the score used for
categorization. Since this decision occurred after sample collection, data for these groups
is listed as Group B/C. Changes in GCS subsequent to triage and trauma assessment did
not affect the categorical placement of the patient samples. Blood was collected in
vacuum tubes containing sodium heparin and processed according to our previously
established protocol12 and under the full approval of Loma Linda Universities
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Institutional Review Board with participating subjects’ permissions obtained

Patient Sample Aggregation
After patient samples were collected, an equal amount of plasma from each
sample was combined with samples from other members of the same trauma severity
category in a single 1.75ml Eppendorf tube belonging to each specific group. Group A’s
aggregated sample contained plasma aliquots from 36 patients (27.4 microliters from
each patient), Group B/C’s aggregated sample contained 17 patients (58.8 microliters
from each patient), and Group D’s aggregated sample contained 25 patient samples (40.0
microliters from each patient). All patient samples analyzed were those from the 24-hour
time point. Each respective Eppendorf was labeled and the raw, untreated plasma
aggregates were sent to SBI (Systems BioSciences, Inc. Mountain View CA) for
exosome separation and analysis.

Exosome Isolation and Characterization
Exosomes were isolated using ExoQuick®, a commercial exosome precipitation
reagent (Systems BioSciences, Inc. Mountain View CA), following the manufacturer’s
protocol. Briefly, plasma samples from individual patients in each GCS group were
pooled and incubated with ExoQuick® overnight at 4°C. Solutions were then centrifuged
at 17,000 x g for 5min and the supernatant discarded. Pellets were resuspended in 100ul
of 1xPBS and analyzed. Analysis of particle size and concentration was determined using
a NS300 Nanosight imager (Malvern Instruments, Inc. Westborough MA) and run at a
dilution of 1:1000.
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Protein Profiling Sample Preparation
Exosomes pellets were lysed in 300μL modified RIPA buffer (2.0% SDS, 150mM
NaCl, 50mM Tris, pH 8.5, 1X Complete Protease inhibitor (Roche, South San Francisco,
CA) at 100°C for 15 minutes. The lysate was clarified by centrifugation and the protein
concentration determined by Qubit fluorometry (Invitrogen, Carlsbad, CA). 10μg of
extracted protein was processed by SDS-PAGE using 10% Bis Tris NuPage mini-gel
(Invitrogen, Carlsbad, CA) in the MES buffer system. The migration window (2cm lane)
was excised and in-gel digestion performed using a ProGest robot (DigiLab,
Marlsbouough, MA) with the following protocol: samples were washed with 25mM
ammonium bicarbonate followed by acetonitrile. Reduced with 10mM dithiothreitol at
60°C followed by alkylation with 50mM iodoacetamide at RT. Digested with sequencing
grade trypsin (Promega, Madison, WI) at 37°C for 4h. Quenched with formic acid and
the supernatant was analyzed directly without further processing.

Mass Spectrometry
Digested samples were analyzed by nano LC-MS/MS with a Waters NanoAcquity
HPLC system (Waters Corporation, Milford, MA) interfaced to a ThermoFisher Q
Exactive (Thermo Fisher Scientific Inc., Canoga Park, CA. Peptides were loaded on a
trapping column and eluted over a 75μm analytical column at 350nL/min using a 2hr
reverse phase gradient; both columns were packed with Luna resin (Phenomenex,
Torrance, CA). The mass spectrometer was operated in data-dependent mode, with the
Orbitrap operating at 60,000 FWHM and 17,500 FWHM for MS and MS/MS
respectively. The fifteen most abundant ions were selected for MS/MS.
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Data Analysis
Scaffold software (Version 4.7, Proteome Software, Inc., Portland, OR) was used
to quantitatively and qualitatively analyze proteomic results. For the purposes of our
analysis the following criteria were utilized: 1.0 False Discovery Rate (FDR), 3.0 as the
minimum number of peptides, and 1.0 FDR as the peptide threshold. Although lower
thresholds yielded a greater number of proteins, it was decided that a higher level of
stringency was preferable in order to assess the feasibility of the exo-proteomic model for
the purposes of our trauma study.

22

Results

Exosomes are Abundantly Present In Plasma and Concentration is Constant between
GCS Groups.
In order to obtain pooled exosomes, an equal amount of plasma from each
individual patient in the GCS group (as described above) was collected and incubated
with ExoQuick® and centrifuged. Vesicles pelleted by this method were then analyzed
by nanoparticle tracking analysis (NTA). This showed, in all three groups, a relatively
narrow size distribution with both the mode and median lying within the exosome
defined size range (Table I, Figure 1). Group A had a mode of 114.3nm and mean of
126.9nm. Group B/C had a mode diameter of 105.7nm and a mean of 128.6nm. Group D
had a mode of 110.1nm and mean of 130.6nm. Concentrations of exosomes between the
groups was also constant with 2.37x1011 particles per mL in group A, 2.38x1011 particles
per mL in group B/C, and 2.04x1011 particles per mL in group D.

Plasma-derived Exosomes from Trauma Patients (TrEx) Contain Potential
Biomarkers.
HPLC analysis of plasma-derived exosomes from 78 trauma patients yielded 186
total categorized proteins (thresholds: 1.0 FDR, 3 peptide minimum, 1.0 FDR peptide
threshold) (Figure 2, Table II). Analysis of these results using Scaffold 4, determined
the number of proteins attributable to biological functions (Figure 3A).
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Table I. Exosome Analysis of The Patient Groups, Size and Concentration.
Group
A

Size (nm)
Mode/Mean
114.3±5.9/126.9±2.8

Concentration
(particles/ml)
2.37x1011±2.28x109

B/C

105.7±0.8/128.6±1.7

2.38x1011±1.08x1010

D

110.1±1.6/130.6±1.0

2.04x1011±7.13x109
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Figure 1. Nanoparticle Size and Concentration as Analyzed on the NTA300
Nanosight. A. Nanoparticle size of plasma vesicles shown as the mean, mode, and
the smallest (D10), middle (D50), and largest particle populations (D90) for
individual groups and composite. B. Comparison of peaks corresponding to the most
abundant vesicular subpopulations.
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Figure 2. Exosomal Protein Enrichment was Monitored in Each Sample by Mass
Spectrometry. Trauma changes were assessed by comparing within the GCS, traumaspecific, exosomal proteomes. A Venn diagram shows the comparison in terms of
exosome proteomes.
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Table II. Exosomal Proteins Found in All Patients.
PROTEINS
Bio View:Identified Proteins (186/231)<BR>Including 0
Decoys

ACCESSION NUMBER
Accession Number

MW
Molecular
Weight

Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M
PE=1 SV=3

sp|P01024|CO3_HUMAN

187 kDa

sp|P01023|A2MG_HUMAN

163 kDa

Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2
Apolipoprotein B-100 OS=Homo sapiens GN=APOB
PE=1 SV=2
Ig gamma-1 chain C region OS=Homo sapiens
GN=IGHG1 PE=1 SV=1
Ig kappa chain C region OS=Homo sapiens GN=IGKC
PE=1 SV=1
Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1
SV=2
Complement C4-B OS=Homo sapiens GN=C4B PE=1
SV=2
Ig gamma-2 chain C region OS=Homo sapiens
GN=IGHG2 PE=1 SV=2
Fibrinogen gamma chain OS=Homo sapiens GN=FGG
PE=1 SV=3
Fibrinogen alpha chain OS=Homo sapiens GN=FGA
PE=1 SV=2
Complement factor H OS=Homo sapiens GN=CFH PE=1
SV=4

sp|P02768|ALBU_HUMAN (+2)

69 kDa

sp|P04114|APOB_HUMAN

516 kDa

sp|P01857|IGHG1_HUMAN

36 kDa

sp|P01834|IGKC_HUMAN

12 kDa

sp|P02675|FIBB_HUMAN

56 kDa

sp|P0C0L5|CO4B_HUMAN

193 kDa

sp|P01859|IGHG2_HUMAN

36 kDa

sp|P02679|FIBG_HUMAN

52 kDa

sp|P02671|FIBA_HUMAN

95 kDa

sp|P08603|CFAH_HUMAN

139 kDa

Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3
Ig mu chain C region OS=Homo sapiens GN=IGHM
PE=1 SV=3

sp|P02787|TRFE_HUMAN

77 kDa

sp|P01871|IGHM_HUMAN

49 kDa

Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4

sp|P01031|CO5_HUMAN

188 kDa

Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1

sp|P00450|CERU_HUMAN

122 kDa

Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1
PE=1 SV=3
Ig alpha-1 chain C region OS=Homo sapiens GN=IGHA1
PE=1 SV=2

sp|P00747|PLMN_HUMAN

91 kDa

sp|P01009|A1AT_HUMAN

47 kDa

sp|P01876|IGHA1_HUMAN

38 kDa

Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4
C4b-binding protein alpha chain OS=Homo sapiens
GN=C4BPA PE=1 SV=2
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1
SV=1
Immunoglobulin lambda-like polypeptide 5 OS=Homo
sapiens GN=IGLL5 PE=2 SV=2

sp|P02751|FINC_HUMAN

263 kDa

sp|P04003|C4BPA_HUMAN

67 kDa

sp|P02647|APOA1_HUMAN

31 kDa

sp|B9A064|IGLL5_HUMAN

23 kDa

Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG
PE=1 SV=1

sp|P00738|HPT_HUMAN

45 kDa

sp|P04196|HRG_HUMAN

60 kDa

Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2

sp|P00734|THRB_HUMAN

70 kDa

Ig gamma-3 chain C region OS=Homo sapiens

sp|P01860|IGHG3_HUMAN

41 kDa
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GN=IGHG3 PE=1 SV=2
Hemoglobin subunit beta OS=Homo sapiens GN=HBB
PE=1 SV=2
Ig kappa chain V-III region HAH OS=Homo sapiens PE=2
SV=1
Complement component C6 OS=Homo sapiens GN=C6
PE=1 SV=3
Ig gamma-4 chain C region OS=Homo sapiens
GN=IGHG4 PE=1 SV=1
Complement C1r subcomponent OS=Homo sapiens
GN=C1R PE=1 SV=2
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1
SV=1
Complement factor B OS=Homo sapiens GN=CFB PE=1
SV=2
Complement component C8 beta chain OS=Homo
sapiens GN=C8B PE=1 SV=3

sp|P68871|HBB_HUMAN

16 kDa

sp|P18135|KV312_HUMAN

14 kDa

sp|P13671|CO6_HUMAN

105 kDa

sp|P01861|IGHG4_HUMAN

36 kDa

sp|P00736|C1R_HUMAN

80 kDa

sp|P02649|APOE_HUMAN

36 kDa

sp|P00751|CFAB_HUMAN

86 kDa

sp|P07358|CO8B_HUMAN

67 kDa

Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2
Keratin, type II cytoskeletal 1 OS=Homo sapiens
GN=KRT1 PE=1 SV=6
C-reactive protein OS=Homo sapiens GN=CRP PE=1
SV=1
Complement C1s subcomponent OS=Homo sapiens
GN=C1S PE=1 SV=1
Alpha-1-antichymotrypsin OS=Homo sapiens
GN=SERPINA3 PE=1 SV=2
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1
SV=1
Complement component C7 OS=Homo sapiens GN=C7
PE=1 SV=2
Vitamin K-dependent protein S OS=Homo sapiens
GN=PROS1 PE=1 SV=1

sp|P02790|HEMO_HUMAN

52 kDa

sp|P04264|K2C1_HUMAN

66 kDa

sp|P02741|CRP_HUMAN

25 kDa

sp|P09871|C1S_HUMAN

77 kDa

sp|P01011|AACT_HUMAN

48 kDa

sp|P01008|ANT3_HUMAN

53 kDa

sp|P10643|CO7_HUMAN

94 kDa

sp|P07225|PROS_HUMAN

75 kDa

Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1
Complement component C8 alpha chain OS=Homo
sapiens GN=C8A PE=1 SV=2

sp|P02760|AMBP_HUMAN

39 kDa

sp|P07357|CO8A_HUMAN

65 kDa

Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2
Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH
PE=1 SV=3
Ig lambda-2 chain C regions OS=Homo sapiens
GN=IGLC2 PE=1 SV=1
Complement C1q subcomponent subunit B OS=Homo
sapiens GN=C1QB PE=1 SV=3

sp|P01042|KNG1_HUMAN

72 kDa

sp|P02749|APOH_HUMAN

38 kDa

sp|P0CG05|LAC2_HUMAN

11 kDa

sp|P02746|C1QB_HUMAN

27 kDa

Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1
Complement component C9 OS=Homo sapiens GN=C9
PE=1 SV=2
Ig heavy chain V-II region ARH-77 OS=Homo sapiens
PE=4 SV=1
Ig heavy chain V-III region TRO OS=Homo sapiens PE=1
SV=1

sp|P10909|CLUS_HUMAN

52 kDa

sp|P02748|CO9_HUMAN

63 kDa

sp|P06331|HV209_HUMAN

16 kDa

sp|P01762|HV301_HUMAN

13 kDa

Apolipoprotein A-IV OS=Homo sapiens GN=APOA4

sp|P06727|APOA4_HUMAN

45 kDa
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PE=1 SV=3
Ig heavy chain V-III region BRO OS=Homo sapiens PE=1
SV=1

sp|P01766|HV305_HUMAN

13 kDa

Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1
Ig kappa chain V-IV region Len OS=Homo sapiens PE=1
SV=2
Ig heavy chain V-III region 23 OS=Homo sapiens
GN=IGHV3-23 PE=1 SV=2
Serum paraoxonase/arylesterase 1 OS=Homo sapiens
GN=PON1 PE=1 SV=3

sp|P06396|GELS_HUMAN

86 kDa

sp|P01625|KV402_HUMAN

13 kDa

sp|P01764|HV303_HUMAN

13 kDa

sp|P27169|PON1_HUMAN

40 kDa

Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1
Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1
SV=2
Actin, cytoplasmic 2 OS=Homo sapiens GN=ACTG1
PE=1 SV=1
Ig heavy chain V-III region GAL OS=Homo sapiens PE=1
SV=1
Complement C4-A OS=Homo sapiens GN=C4A PE=1
SV=2
Complement factor I OS=Homo sapiens GN=CFI PE=1
SV=2
Ig kappa chain V-I region DEE OS=Homo sapiens PE=1
SV=1
Haptoglobin-related protein OS=Homo sapiens
GN=HPR PE=2 SV=2
Complement component C8 gamma chain OS=Homo
sapiens GN=C8G PE=1 SV=3
Galectin-3-binding protein OS=Homo sapiens
GN=LGALS3BP PE=1 SV=1

sp|P04004|VTNC_HUMAN

54 kDa

sp|P07996|TSP1_HUMAN

129 kDa

sp|P63261|ACTG_HUMAN

42 kDa

sp|P01781|HV320_HUMAN

13 kDa

sp|P0C0L4|CO4A_HUMAN

193 kDa

sp|P05156|CFAI_HUMAN

66 kDa

sp|P01597|KV105_HUMAN

12 kDa

sp|P00739|HPTR_HUMAN

39 kDa

sp|P07360|CO8G_HUMAN

22 kDa

sp|Q08380|LG3BP_HUMAN

65 kDa

Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2
Coagulation factor XIII B chain OS=Homo sapiens
GN=F13B PE=1 SV=3

sp|O75636|FCN3_HUMAN

33 kDa

sp|P05160|F13B_HUMAN

76 kDa

Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3
Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1
PE=1 SV=3
Lipopolysaccharide-binding protein OS=Homo sapiens
GN=LBP PE=1 SV=3
Ig kappa chain V-III region B6 OS=Homo sapiens PE=1
SV=1
Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2
PE=1 SV=3
Ig kappa chain V-I region Gal OS=Homo sapiens PE=1
SV=1

sp|Q9Y490|TLN1_HUMAN

270 kDa

sp|P05546|HEP2_HUMAN

57 kDa

sp|P18428|LBP_HUMAN

53 kDa

sp|P01619|KV301_HUMAN

12 kDa

sp|P08697|A2AP_HUMAN

55 kDa

sp|P01599|KV107_HUMAN

12 kDa

Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 SV=4
Ig heavy chain V-III region GA OS=Homo sapiens PE=1
SV=1
Serum amyloid P-component OS=Homo sapiens
GN=APCS PE=1 SV=2
Complement C1q subcomponent subunit C OS=Homo
sapiens GN=C1QC PE=1 SV=3

sp|P23142|FBLN1_HUMAN

77 kDa

sp|P01769|HV308_HUMAN

13 kDa

sp|P02743|SAMP_HUMAN

25 kDa

sp|P02747|C1QC_HUMAN

26 kDa

29

Plasma kallikrein OS=Homo sapiens GN=KLKB1 PE=1
SV=1
Plasma protease C1 inhibitor OS=Homo sapiens
GN=SERPING1 PE=1 SV=2
Ig heavy chain V-I region 5 (Fragment) OS=Homo
sapiens GN=IGKV1-5 PE=4 SV=2
Complement C1q subcomponent subunit A OS=Homo
sapiens GN=C1QA PE=1 SV=2
Ig kappa chain V-I region EU OS=Homo sapiens PE=1
SV=1
Ig delta chain C region OS=Homo sapiens GN=IGHD
PE=1 SV=2
Angiotensinogen OS=Homo sapiens GN=AGT PE=1
SV=1
Insulin-like growth factor-binding protein complex acid
labile subunit OS=Homo sapiens GN=IGFALS PE=1 SV=1
N-acetylmuramoyl-L-alanine amidase OS=Homo
sapiens GN=PGLYRP2 PE=1 SV=1
Retinol-binding protein 4 OS=Homo sapiens GN=RBP4
PE=1 SV=3
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG
PE=1 SV=1
Complement C2 OS=Homo sapiens GN=C2 PE=1 SV=2
Leucine-rich alpha-2-glycoprotein OS=Homo sapiens
GN=LRG1 PE=1 SV=2
Ig heavy chain V-I region EU OS=Homo sapiens PE=1
SV=1
Immunoglobulin J chain OS=Homo sapiens GN=JCHAIN
PE=1 SV=4
Pigment epithelium-derived factor OS=Homo sapiens
GN=SERPINF1 PE=1 SV=4
Ig alpha-2 chain C region OS=Homo sapiens GN=IGHA2
PE=1 SV=3
Alpha-1-acid glycoprotein 2 OS=Homo sapiens
GN=ORM2 PE=1 SV=2
Apolipoprotein A-II OS=Homo sapiens GN=APOA2
PE=1 SV=1
C4b-binding protein beta chain OS=Homo sapiens
GN=C4BPB PE=1 SV=1
Complement factor H-related protein 1 OS=Homo
sapiens GN=CFHR1 PE=1 SV=2
Ig heavy chain V-III region CAM OS=Homo sapiens
PE=1 SV=1
Ig lambda chain V-III region LOI OS=Homo sapiens
PE=1 SV=1
Coagulation factor XIII A chain OS=Homo sapiens
GN=F13A1 PE=1 SV=4
Ig lambda chain V-I region HA OS=Homo sapiens PE=1
SV=1
Apolipoprotein D OS=Homo sapiens GN=APOD PE=1
SV=1
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sp|P03952|KLKB1_HUMAN

71 kDa

sp|P05155|IC1_HUMAN

55 kDa

sp|P01602|KV110_HUMAN

13 kDa

sp|P02745|C1QA_HUMAN

26 kDa

sp|P01598|KV106_HUMAN

12 kDa

sp|P01880|IGHD_HUMAN

42 kDa

sp|P01019|ANGT_HUMAN

53 kDa

sp|P35858|ALS_HUMAN

66 kDa

sp|Q96PD5|PGRP2_HUMAN

62 kDa

sp|P02753|RET4_HUMAN

23 kDa

sp|P02765|FETUA_HUMAN

39 kDa

sp|P06681|CO2_HUMAN

83 kDa

sp|P02750|A2GL_HUMAN

38 kDa

sp|P01742|HV101_HUMAN

12 kDa

sp|P01591|IGJ_HUMAN

18 kDa

sp|P36955|PEDF_HUMAN

46 kDa

sp|P01877|IGHA2_HUMAN

37 kDa

sp|P19652|A1AG2_HUMAN

24 kDa

sp|P02652|APOA2_HUMAN

11 kDa

sp|P20851|C4BPB_HUMAN

28 kDa

sp|Q03591|FHR1_HUMAN

38 kDa

sp|P01768|HV307_HUMAN

14 kDa

sp|P80748|LV302_HUMAN

12 kDa

sp|P00488|F13A_HUMAN

83 kDa

sp|P01700|LV102_HUMAN

12 kDa

sp|P05090|APOD_HUMAN

21 kDa

Ig kappa chain V-III region CLL OS=Homo sapiens PE=4
SV=2
Ig heavy chain V-I region HG3 OS=Homo sapiens PE=3
SV=1
Alpha-1-acid glycoprotein 1 OS=Homo sapiens
GN=ORM1 PE=1 SV=1

sp|P04207|KV308_HUMAN

14 kDa

sp|P01743|HV102_HUMAN

13 kDa

sp|P02763|A1AG1_HUMAN

24 kDa

Catalase OS=Homo sapiens GN=CAT PE=1 SV=3
Carboxypeptidase N subunit 2 OS=Homo sapiens
GN=CPN2 PE=1 SV=3
Ig kappa chain V-III region NG9 (Fragment) OS=Homo
sapiens PE=2 SV=1
Ig kappa chain V-I region Mev OS=Homo sapiens PE=1
SV=1
Ig heavy chain V-III region HIL OS=Homo sapiens PE=1
SV=1
von Willebrand factor OS=Homo sapiens GN=VWF
PE=1 SV=4
Coagulation factor IX OS=Homo sapiens GN=F9 PE=1
SV=2
Ig kappa chain V-II region RPMI 6410 OS=Homo
sapiens PE=4 SV=1
Hepatocyte growth factor-like protein OS=Homo
sapiens GN=MST1 PE=1 SV=2
Apolipoprotein M OS=Homo sapiens GN=APOM PE=1
SV=2
Ig kappa chain V-III region VG (Fragment) OS=Homo
sapiens PE=1 SV=1

sp|P04040|CATA_HUMAN

60 kDa

sp|P22792|CPN2_HUMAN

61 kDa

sp|P01621|KV303_HUMAN

11 kDa

sp|P01612|KV120_HUMAN

12 kDa

sp|P01771|HV310_HUMAN

14 kDa

sp|P04275|VWF_HUMAN

309 kDa

sp|P00740|FA9_HUMAN

52 kDa

sp|P06310|KV206_HUMAN

15 kDa

sp|P26927|HGFL_HUMAN

80 kDa

sp|O95445|APOM_HUMAN

21 kDa

sp|P04433|KV309_HUMAN

13 kDa

Properdin OS=Homo sapiens GN=CFP PE=1 SV=2
Ig kappa chain V-I region WEA OS=Homo sapiens PE=1
SV=1
Ig kappa chain V-II region TEW OS=Homo sapiens PE=1
SV=1
Carboxypeptidase B2 OS=Homo sapiens GN=CPB2
PE=1 SV=2
Ig kappa chain V-I region CAR OS=Homo sapiens PE=1
SV=1
Ig lambda-7 chain C region OS=Homo sapiens
GN=IGLC7 PE=4 SV=2

sp|P27918|PROP_HUMAN

51 kDa

sp|P01610|KV118_HUMAN

12 kDa

sp|P01617|KV204_HUMAN

12 kDa

sp|Q96IY4|CBPB2_HUMAN

48 kDa

sp|P01596|KV104_HUMAN

12 kDa

sp|A0M8Q6|LAC7_HUMAN

11 kDa

Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4
Ig lambda chain V-V region DEL OS=Homo sapiens
PE=1 SV=1
Ig heavy chain V-III region BUT OS=Homo sapiens PE=1
SV=1
Ig kappa chain V-I region AG OS=Homo sapiens PE=1
SV=1
Transforming growth factor-beta-induced protein igh3 OS=Homo sapiens GN=TGFBI PE=1 SV=1
Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1
SV=2

sp|P21333|FLNA_HUMAN

281 kDa

sp|P01719|LV501_HUMAN

11 kDa

sp|P01767|HV306_HUMAN

12 kDa

sp|P01593|KV101_HUMAN

12 kDa

sp|Q15582|BGH3_HUMAN

75 kDa

sp|P12814|ACTN1_HUMAN

103 kDa

Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 SV=2

sp|Q15485|FCN2_HUMAN

34 kDa
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Ig lambda chain V-III region SH OS=Homo sapiens PE=1
SV=1
Coagulation factor XII OS=Homo sapiens GN=F12 PE=1
SV=3
Plasma serine protease inhibitor OS=Homo sapiens
GN=SERPINA5 PE=1 SV=3
Ig lambda chain V-I region NEW OS=Homo sapiens
PE=1 SV=1
Ig lambda chain V-II region NIG-84 OS=Homo sapiens
PE=1 SV=1
Ig heavy chain V-III region WEA OS=Homo sapiens
PE=1 SV=1
Hemoglobin subunit delta OS=Homo sapiens GN=HBD
PE=1 SV=2
Coagulation factor V OS=Homo sapiens GN=F5 PE=1
SV=4
Extracellular matrix protein 1 OS=Homo sapiens
GN=ECM1 PE=1 SV=2
Glyceraldehyde-3-phosphate dehydrogenase
OS=Homo sapiens GN=GAPDH PE=1 SV=3
Ig kappa chain V-II region MIL OS=Homo sapiens PE=1
SV=1
Putative V-set and immunoglobulin domaincontaining-like protein IGHV4OR15-8 OS=Homo
sapiens GN=IGHV4OR15-8 PE=5 SV=2
Ig lambda chain V-II region NEI OS=Homo sapiens PE=1
SV=1
Band 3 anion transport protein OS=Homo sapiens
GN=SLC4A1 PE=1 SV=3
Peroxiredoxin-2 OS=Homo sapiens GN=PRDX2 PE=1
SV=5

sp|P01714|LV301_HUMAN

11 kDa

sp|P00748|FA12_HUMAN

68 kDa

sp|P05154|IPSP_HUMAN

46 kDa

sp|P01701|LV103_HUMAN

11 kDa

sp|P04209|LV211_HUMAN

12 kDa

sp|P01763|HV302_HUMAN

12 kDa

sp|P02042|HBD_HUMAN

16 kDa

sp|P12259|FA5_HUMAN

252 kDa

sp|Q16610|ECM1_HUMAN

61 kDa

sp|P04406|G3P_HUMAN

36 kDa

sp|P01616|KV203_HUMAN

12 kDa

sp|A6NJ16|IV4F8_HUMAN

14 kDa

sp|P01705|LV202_HUMAN

12 kDa

sp|P02730|B3AT_HUMAN

102 kDa

sp|P32119|PRDX2_HUMAN

22 kDa

Tetranectin OS=Homo sapiens GN=CLEC3B PE=1 SV=3
Serum amyloid A-1 protein OS=Homo sapiens
GN=SAA1 PE=1 SV=1
L-lactate dehydrogenase A chain OS=Homo sapiens
GN=LDHA PE=1 SV=2
Complement factor H-related protein 5 OS=Homo
sapiens GN=CFHR5 PE=1 SV=1
Mannose-binding protein C OS=Homo sapiens
GN=MBL2 PE=1 SV=2
EGF-containing fibulin-like extracellular matrix protein
1 OS=Homo sapiens GN=EFEMP1 PE=1 SV=2
Ig kappa chain V-I region Kue OS=Homo sapiens PE=1
SV=1
Ig kappa chain V-IV region STH (Fragment) OS=Homo
sapiens PE=1 SV=1
Ig kappa chain V-I region Roy OS=Homo sapiens PE=1
SV=1
Coagulation factor XI OS=Homo sapiens GN=F11 PE=1
SV=1

sp|P05452|TETN_HUMAN

23 kDa

sp|P0DJI8|SAA1_HUMAN

14 kDa

sp|P00338|LDHA_HUMAN

37 kDa

sp|Q9BXR6|FHR5_HUMAN

64 kDa

sp|P11226|MBL2_HUMAN

26 kDa

sp|Q12805|FBLN3_HUMAN

55 kDa

sp|P01604|KV112_HUMAN

12 kDa

sp|P83593|KV405_HUMAN

12 kDa

sp|P01608|KV116_HUMAN

12 kDa

sp|P03951|FA11_HUMAN

70 kDa

Protein S100-A9 OS=Homo sapiens GN=S100A9 PE=1

sp|P06702|S10A9_HUMAN

13 kDa
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SV=1
Polymeric immunoglobulin receptor OS=Homo sapiens
GN=PIGR PE=1 SV=4
Phosphatidylinositol-glycan-specific phospholipase D
OS=Homo sapiens GN=GPLD1 PE=1 SV=3
Ig heavy chain V-II region WAH OS=Homo sapiens PE=1
SV=1
Ig heavy chain V-III region BUR OS=Homo sapiens PE=1
SV=1
Apolipoprotein C-III OS=Homo sapiens GN=APOC3
PE=1 SV=1
Ig kappa chain V-I region Rei OS=Homo sapiens PE=1
SV=1
Mannan-binding lectin serine protease 1 OS=Homo
sapiens GN=MASP1 PE=1 SV=3
Zinc-alpha-2-glycoprotein OS=Homo sapiens
GN=AZGP1 PE=1 SV=2

sp|P01833|PIGR_HUMAN

83 kDa

sp|P80108|PHLD_HUMAN

92 kDa

sp|P01824|HV206_HUMAN

14 kDa

sp|P01773|HV312_HUMAN

13 kDa

sp|P02656|APOC3_HUMAN

11 kDa

sp|P01607|KV115_HUMAN

12 kDa

sp|P48740|MASP1_HUMAN

79 kDa

sp|P25311|ZA2G_HUMAN

34 kDa

Adiponectin OS=Homo sapiens GN=ADIPOQ PE=1 SV=1
Ig lambda chain V region 4A OS=Homo sapiens PE=4
SV=1
Ig kappa chain V-III region GOL OS=Homo sapiens PE=1
SV=1
78 kDa glucose-regulated protein OS=Homo sapiens
GN=HSPA5 PE=1 SV=2
Sulfhydryl oxidase 1 OS=Homo sapiens GN=QSOX1
PE=1 SV=3
Ig lambda chain V-II region BUR OS=Homo sapiens
PE=1 SV=1
Apolipoprotein C-I OS=Homo sapiens GN=APOC1 PE=1
SV=1
Protein S100-A8 OS=Homo sapiens GN=S100A8 PE=1
SV=1

sp|Q15848|ADIPO_HUMAN

26 kDa

sp|P04211|LV001_HUMAN

12 kDa

sp|P04206|KV307_HUMAN

12 kDa

sp|P11021|GRP78_HUMAN

72 kDa

sp|O00391|QSOX1_HUMAN

83 kDa

sp|P01708|LV205_HUMAN

12 kDa

sp|P02654|APOC1_HUMAN

9 kDa

sp|P05109|S10A8_HUMAN

11 kDa

Lumican OS=Homo sapiens GN=LUM PE=1 SV=2
Monocyte differentiation antigen CD14 OS=Homo
sapiens GN=CD14 PE=1 SV=2
Complement factor D OS=Homo sapiens GN=CFD PE=1
SV=5

sp|P51884|LUM_HUMAN

38 kDa

sp|P08571|CD14_HUMAN

40 kDa

sp|P00746|CFAD_HUMAN

27 kDa

Talin-2 OS=Homo sapiens GN=TLN2 PE=1 SV=4
Ig kappa chain V-I region Ka OS=Homo sapiens PE=1
SV=1
Fermitin family homolog 3 OS=Homo sapiens
GN=FERMT3 PE=1 SV=1

sp|Q9Y4G6|TLN2_HUMAN

272 kDa

sp|P01603|KV111_HUMAN

12 kDa

sp|Q86UX7|URP2_HUMAN

76 kDa

Alpha-enolase OS=Homo sapiens GN=ENO1 PE=1 SV=2
Carbamoyl-phosphate synthase [ammonia],
mitochondrial OS=Homo sapiens GN=CPS1 PE=1 SV=2
Abnormal spindle-like microcephaly-associated protein
OS=Homo sapiens GN=ASPM PE=1 SV=2

sp|P06733|ENOA_HUMAN

47 kDa

sp|P31327|CPSM_HUMAN

165 kDa

sp|Q8IZT6|ASPM_HUMAN

410 kDa

Titin OS=Homo sapiens GN=TTN PE=1 SV=4

sp|Q8WZ42|TITIN_HUMAN

3816 kDa
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Figure 3. Trauma Exosome Protein Localization. A. Exosomal proteins were
categorized for their biological function. B. Exosomal proteins were next categorized
according to their molecular function. C. Exosomal proteins were next categorized as to
their cellular component.
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Proteins possessed the following 19 biological functions: Biological Regulation (186),
Biological Process (186), Cellular Process (183), Stimulus Response (165), Metabolic
Process (147), Localization (131), Establishment of Localization (125), Multicellular
Organismal Process (82), Developmental Process (56), Multi-organism Process (39),
Biological Adhesion (16), Locomotion (15), Reproductive Process (9), Reproduction (9),
Viral Replication (9), Growth (6) Cell Killing (3), and Rhythmic Process (3). Proteins
were further stratified according to Molecular Function (Figure 3B) and Cellular
Compartments (Figure 3C). The proteins possessed the following 13 molecular
functions: undetermined molecular function (171), Binding (158), Chemoattractant
activity (1), Chemorepellent activity (1), Transcription regulator activity (2), Auxiliary
transport protein activity (3), Antioxidant activity (8), Structural molecule activity (10),
Molecular transducer activity (13), Transporter activity (14), Enzyme regulator activity
(29), Catalytic activity (93), and Unknown (15) (Figure 3B). The proteins represented
14 different cellular compartments: Extracellular region (182), Membrane (128),
Ribosome (1), Mitochondrion (4), Endosome (8), Golgi apparatus (14), Endoplasmic
reticulum (14), Cytoskeleton (15), Organelle membrane (15), Nucleus (21), Organelle
part (56), Cytoplasm (71), Intracellular organelle (73) and Plasma membrane (118)
(Figure 3C).

Protein Expression Across Different GCS Classifications.
Of the 186 total proteins found, 134 were held in common between all three
experimental groups (Figure 2 and Table I). Additionally, sixteen were shared between
two groups (Table III). Specifically, between Groups A (No Significant Trauma) and
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B/C (Mild-to-Moderate Trauma) nine proteins were found to be in common: Ig kappa
chain V-III region B6, Ig lambda chain V-III region LOI, Ig heavy chain V-I region HG3,
Hemoglobin subunit delta, Peroxiredoxin-2, Coagulation factor XI, Polymeric
immunoglobulin receptor, Phosphatidylinositol-glycan-specific phospholipase D, and
Apolipoprotein C-III. Groups B/C (Mild-to-Moderate Trauma) and D (Severe Trauma),
shared four proteins: Ig heavy chain V-III region HIL, von Willebrand factor,
Coagulation factor V, and Mannan-binding lectin serine protease. Between our two most
disparate groups of trauma patients, groups A (No Significant Trauma) and D (Severe
Trauma), three (3) proteins were found to be present in both patient subsets: Ig lambda
chain V-II region NEI, L-lactate dehydrogenase A chain, and Ig kappa chain V-IV region
STH (Fragment). All of the proteins found to be present in two groups are found in Table
III. However, differential proteomic expression was observed between our stratified GCS
classifications as 6 of these proteins were found only in patients that had suffered no
significant trauma as denoted by GCS score (15): Ig kappa chain V-III region NG9,
Protein S100-A9, Apolipoprotein C-I, Ig kappa chain V-I region Ka, Fermitin family
homolog 3, and Alpha-enolase (Table IV). Sixteen proteins were unique to patients that
had mild-to-moderate trauma as designated by GCS Score (9-12): Ig kappa chain V-I
region Gal, Ig kappa chain V-I region EU, Ig kappa chain V-III region CLL, Ig kappa
chain V-II region TEW, Ig heavy chain V-III region WEA, Tetranectin, EGF-containing
fibulin-like extracellular matrix protein 1, Adiponectin, Ig lambda chain V region 4A,
Sulfhydryl oxidase 1, Protein S100-A8, Lumican, Complement factor D, Talin-2,
Abnormal spindle-like microcephaly-associated protein, and Titin (Table IV).
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Table III. Proteins Held in Common by Two or more groups.
Groups A and B/C: 9 Proteins
Ig kappa chain V-III region B6
Ig lambda chain V-III region
LOI
Ig heavy chain V-I region HG3

Groups A and D: 3
Proteins
Ig lambda chain V-II
region NEI
L-lactate dehydrogenase
A chain
Ig kappa chain V-IV
region STH (Fragment)

Hemoglobin subunit delta
Peroxiredoxin-2
Coagulation factor XI
Polymeric immunoglobulin
receptor
Phosphatidylinositol-glycanspecific phospholipase D
Apolipoprotein C-III
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Groups B/C and D: 4
Proteins
Ig heavy chain V-III
region HIL
von Willebrand factor
Coagulation factor V
Mannan-binding lectin
serine protease 1

Table IV. List of Group Specific Proteins
Group A: 6 Proteins

Group B/C: 16 Proteins

Ig kappa chain V-III
region NG9 (Fragment)

Ig kappa chain V-I region
Gal
Ig kappa chain V-I region
Protein S100-A9
EU
Ig kappa chain V-III region
Apolipoprotein C-I
CLL
Ig kappa chain V-I region
Ig kappa chain V-II region
Ka
TEW
Ig heavy chain V-III region
Fermitin family homolog 3 WEA
Alpha-enolase

Tetranectin
EGF-containing fibulin-like
extracellular matrix protein
1
Adiponectin
Ig lambda chain V region
4A
Sulfhydryl oxidase 1
Protein S100-A8
Lumican

Complement factor D
Talin-2
Abnormal spindle-like
microcephaly-associated
protein
Titin
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Group D: 14 Proteins
Ig kappa chain V-I region
AG
Ig lambda chain V-II
region NIG-84
Mannose-binding protein
C
Ig kappa chain V-I region
Roy
Ig heavy chain V-II region
WAH
Ig heavy chain V-III
region BUR
Ig kappa chain V-I region
Rei
Zinc-alpha-2-glycoprotein
Ig kappa chain V-III
region GOL
78 kDa glucose-regulated
protein
Ig lambda chain V-II
region BUR
Monocyte differentiation
antigen CD14
Carbamoyl-phosphate
synthase (ammonia),
mitochondrial
Ig heavy chain V-III
region BUT

Fourteen (14) proteins were found only in patients that had suffered significant trauma as
designated by GCS score (3-8): Ig kappa chain V-I region AG, Ig lambda chain V-II
region NIG-84, Mannose-binding protein C, Ig kappa chain V-I region Roy, Ig heavy
chain V-II region WAH, Ig heavy chain V-III region BUR, Ig kappa chain V-I region Rei
Zinc-alpha-2-glycoprotein, Ig kappa chain V-III region GOL, 78 kDa glucose-regulated
protein, Ig lambda chain V-II region BUR, Monocyte differentiation antigen CD14, and
Carbamoyl-phosphate synthase (ammonia), mitochondrial (Table IV).
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Discussion
The natural history of mild traumatic brain injury (TBI) or concussion remains
poorly defined and no objective biomarker of physiological recovery exists for clinical
use 13. The National Collegiate Athletic Association (NCAA) and the US Department of
Defense (DoD) established the Concussion Assessment, Research and Education (CARE)
Consortium to study the natural history of clinical and neurobiological recovery after
concussion in the service of improved injury prevention, safety and medical care for
student-athletes and military personnel 14. Concussion and mTBI research to date has
largely focused on male athletes in contact sports and has largely ignored the military and
women13. In addition, most of the assessments have been non-molecular, focused on
imaging and physical diagnosis.
The objective of this study was to determine if the addition of molecular
biomarkers to the physical diagnosis could lead to understanding that would allow injury
severity to be determined. Exosomal protein analysis of clinical trauma samples taken
from patients with varying Glasgow Coma Scale (GCS) scores assessed the differential
protein expression between strata used to define the severity of head injury. ExoProteomic analysis of patients with disparate levels of “trauma severity” lends itself well
to the discovery of potential trauma-specific biomarkers that can help establish the first
true differential diagnostic for concussions and mTBI. Utilization of these trauma
exosomes (TrEx) helps assure that sensitive proteins are still detectable in a post-acute
phase of head injury, regardless of the degree of severity. Additionally, coupling exoproteomic analysis with a non-invasive peripheral blood sample could aid in the
establishment of a de facto “liquid biopsy” for the assessment of all varieties of TBI.
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Our results indicate that patient groups with varying GCS scores do exhibit
differential protein expression in their exosomes. An important limitation of this study is
the small number of patients that were available for each GCS-categorized group.
However, we were still able to observe differences in exosomal protein expression
between our study groups. While we discovered no putative markers of TBI in our
analysis and our patient samples were aggregated rather than analyzed individually, the
results of this work indicate a proof of concept that helps validate an exo-proteomic
approach for the study of traumatic brain injury. Not all patients were verified to have
TBI as detailed injury descriptions were not given. The ongoing and next steps in
exosome research include refining the isolation procedure for exosomes, defining the
appropriate window for isolation, determine what contents are most important for
diagnosis: mRNAs, miRNAs, lipids and proteins, and to determine which exosomes can
and cannot cross the blood brain barrier. Further patient studies comparing exosomal
patient samples would be best served if comparative proteomic analysis were stratified
according to patient populations representing both verified TBIs as compared to non-TBI
related injuries. This would aid analysis and help guide the search for definitive TBIrelated biomarkers. The single greatest challenge facing any clinical study of TBI-related
proteomics is the inherent limitations of the GCS itself. GCS scoring and stratification
lacks definitive prognostic value, including significant variances in head injury patterns
and exhibit the potential for skewed triage and treatment due to unrelated factors such as
hemorrhagic shock and other acute phenomena. Additional measures of injury
assessment (such as Injury Severity Score, for example) need to be factored in when
designing and implementing further exo-proteomic studies of TBI.
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We thank Dr. Wu and his colleagues1 for critically reviewing our study to
establish a panel of trauma markers to increase the likelihood of successfully diagnosing,
treating and predicting concussions and traumatic brain injuries (TBI)2. We do not
disagree that a different baseline of patients’ demographic characteristics in the groups
that we chose, based solely on the Glasgow Comma Score (GCS), could cause possible
bias. In fact, though our results did indicate that patient groups with varying GCS scores
did exhibit differential protein expression in their exosomes, we clearly state many
limitations in the study. Of note, not all the patients had verified TBI and perhaps most
significant, these results were from aggregated patient samples rather than from patients
analyzed individually. Nevertheless, this manuscript’s intent was to report a proof of
concept, that the exo-proteomic approach could be useful in the study of traumatic brain
injury and that the ongoing and next steps in exosome research include refining the
isolation procedure for exosomes, defining the appropriate window for isolation,
determine what contents are most important for diagnosis: mRNAs, miRNAs, DNA,
lipids and proteins, and to determine which exosomes can and cannot cross the blood
brain barrier2. We thank Dr. Wu and colleagues for their comments1 as we recognize the
value in determining if patient demographics such as age, gender and perhaps even ethnic
origin could present disparity expression of exosomal biomarkers or the quantity of a
specific or panel of biomarkers. However, discovery of this marker or marker panel to
determine severity of injury would be best served if comparative proteomic analysis were
stratified according to patient populations representing both verified TBI as compared to
non-TBI related injuries. This would aid analysis and help guide the search for definitive
TBI-related biomarkers of TBI severity. This work was not meant to be supportive but to
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expose the limitations of the GCS itself in defining the level of trauma a patient having
TBI would have and their prognosis and recovery. GCS scoring and stratification lacks
definitive prognostic value3, including significant variances in head injury patterns and
exhibit the potential for skewed triage and treatment due to unrelated factors such as
hemorrhagic shock and other acute phenomena4.
With that in mind, the current criteria used for evaluation of concussive trauma
are outdated5 and are limited to the assessment of behavioral symptoms6,7. This standard
for diagnosis is woefully insufficient, even when coupled with GCS score, Injury
Severity Score (ISS) and other predominately utilized clinical modalities8. This fact is
becoming increasingly clear, not due solely to the subjective nature of emergency
department assessments of injury severity, but rather to the vastly differing presentations
of traumatic brain injuries and the relative lack of primacy placed upon them in relation
to more “significant” injuries with more obvious gross damage8. The current modalities
need to be supplemented with proteomic profiling that is specifically tailored to the
definitive diagnosis of concussive or sub-concussive trauma9,10.
Continuing research of concussions and TBI would be best served by utilizing a
multifactorial, multidisciplinary approach. Future studies could compare exosomal
proteomic profiling of patients with verified TBI (SAH, SDH and ICH for example), as
stratified according to significant findings on radiologic studies or other scans (fMRI,
MRI, CT) compared with those of patients with similar injury mechanisms (automobile
vs. pedestrian, motor vehicle accidents, assaults, blunt and penetrating trauma) that do not
have verifiable TBI11,12. GCS scores should still be utilized, however adhering to the
present GCS categorical stratifications (mild vs. moderate vs. severe) as the primary
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stratification tool and essential factor for patient enrollment would be inadvisable. In
addition, after admission and assessment, the ideal enrolled patients would need to be
assessed and/or treated by multiple in-patient and out-patient services (orthopedics,
neurosurgery, acute care surgery, emergency medicine etc.) and receive care “in
concert”13. Ideally, treatment of symptomology and outcome assessment would be a
cross-pollination of work from diverse clinical and research disciplines such as
psychology, psychiatry, and neuroscience.
In addition, Next Generation Sequencing (NGS) of total exosomal RNA can, and
should, be analyzed concurrently with exosomal proteomic analysis. Combining both
NGS and proteomic analysis might ultimately lead to the establishment of a fuller picture
of the underlying systemic impact of head trauma and a greater understanding of the
acute phases of concussive and sub concussive trauma, disease progression, and predict
the early onset of post concussive syndrome (PCS) and chronic traumatic encephalopathy
14,15
. Ideally, the best approach is non-invasive or minimally invasive. Non(CTE)

invasive methods, such as a peripheral blood draw, coupled with exo-proteomic analysis
lend themselves exceptionally well to this type of biomarker discovery and the potential
establishment of a de facto “liquid biopsy” for the diagnosis of head trauma16,17.
While the search for novel biomarkers of head trauma continues, delineating their
prognostic value in terms of recovery, return to activity and likelihood of worsening
symptoms is of critical importance. It is highly likely that the best diagnostic and
prognostic tools will be a panel of existing markers of neuronal trauma combined with as
of yet undiscovered markers. Even in the case where the best diagnostic tool is a panel of
existing known markers of neuronal trauma (e.g. Tau, NSE, S100B, etc.)3,18-21, baseline
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amounts of these existing markers will need to be established in (relatively) healthy,
symptom-free individuals and compared with known head trauma patients. It will also
need to be established what level of these markers is indicative of cellular damage and
what basal level is elicited in normal cellular repair and turnover.
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CHAPTER FOUR
CONCLUSION
The current understanding of head trauma views concussion and TBI as injuries
that exist along a spectrum, rather than as discrete events. The mildest head injuries are
termed subconcussive trauma and the most chronic, debilitating events lead to profound
systemic dysregulation known as Chronic Traumatic Encephalopathy (CTE).
Subconcussive events are believed to be those injuries that incur brain damage but do not
result in noticeable symptoms. More severe than subconcussive events are minor
traumatic brain injuries where the head either strikes, or is struck by, an object. During
impact to the head, the brain is pushed against the inside of the skull which can cause
bruising, bleeding, and tearing of nerve fibers. Although widely varied, symptoms of a
concussion can include headache, dizziness, slurred speech and fatigue among many
others. Usually, given time and adequate rest (or cessation of at risk activity) the
symptoms of a concussion resolve within 10 days. However, if these symptoms persist,
the classification of the injury changes and is dependent upon the length of time before
symptom resolution. If symptoms linger for longer than 10 days but less than
approximately 3 months, the concussion has become a concussive syndrome. If
symptoms persist for longer than 3 months, up to and including several years, the injury
is no longer seen as a single episodic event and is termed post concussive syndrome. If
the symptoms become pervasive and/or permanent, this chronic outgrowth of head
trauma is known as Chronic Traumatic Encephalopathy (CTE). Currently, the only
definitive diagnosis for CTE is a post-mortem examination of brain tissue. Most
tragically, the clinical features of CTE often mirror characteristic of Parkinson’s Disease
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and Alzheimer’s Disease and like these two devastating conditions there is no known
cure for the malady of CTE. A graphical depiction of the spectrum of head trauma can be
found in Figure 4.

Figure 4. The Spectrum of Traumatic Brain Injury (TBI).

The constellation of symptoms following a concussion or head trauma is both
complex and problematic. Proper diagnosis, treatment, and prediction of outcomes
following any gradation of head injury is difficult and prone to significant error and
subjective bias. Due to the heterogeneity of symptom presentation and the disparate
factors underlying pathology, in addition to probable genetic precursors (ApoE4 allelic
inheritance for example), accurate assessment of injury, severity, and recovery are nearly
impossible at this juncture.
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Despite the greater awareness and pronounced increase in funding of research into
traumatic brain injuries, TBI still impose a significant societal burden in terms of lost
work time, medical care costs, and neuropsychiatric complications. Each year in the
United States at least 1,700,000 people sustain TBI. This includes 52,000 deaths, 275,000
hospitalizations, and 1,365,000 patients treated and released from an emergency
department. TBI is a contributing factor to 30% of all injury related deaths in the United
States. It is estimated that 3,200,000–5,300,000 persons currently live with long-term
physical and neuropsychiatric disabilities attributable to TBI (Murray and Lopez, 1997).
Even with the increased focus on the assessment of TBI of all severities, much work
remains to be done to fully elucidate the various causes and outcomes along the spectrum
of injuries. Following the publication of the preceding work, significant cross-modal,
multi-center studies in TBI risk factors, etiology, assessment and outcomes have been
undertaken (Yue, Vassar, Lingsma et al, 2013), with varying degrees of success.
Researchers are increasingly skeptical of the discovery of the “magic bullet”, one-sizefits-all biomarker of neuronal or systemic damage as a clear, indisputable indicator of
traumatic brain injury. Current studies are shifting the onus towards the formulation of
the aforementioned “trauma panel”: a compendium of proteins or biomarkers whose
dysregulation and presence in CSF or the peripheral blood may be indicative of a level of
central nervous system disruption, neuronal damage or systemic loss of homeostatic
balance. Recently, the Food and Drug Administration approved a “concussion test” via
peripheral blood draw, that assesses the presence/level of a pair of proteins in the
peripheral blood: GFAP and UCH-L1at 12 hours after a suspected injury. This is exciting
news because we specifically highlighted these proteins, amongst others, earlier in this
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work; however, this is only one of many steps that need to be undertaken to paint a fuller
picture of this troubling disease/condition.
These new discoveries and the renewed focus on the course and impact of TBI
have laid the groundwork for some truly novel experimental approaches and
collaborative efforts. Perhaps some of the most fertile and untapped territory, however, is
the design and implementation of head injury studies focusing on armed services
personnel currently deployed, or returning from deployment, in the Middle East and other
combat zones. Significant numbers of men and women in uniform sustain TBI resulting
from, and in conjunction with, injuries sustained in combat. In contrast to even some of
the most rigorously designed multi-center studies of head trauma in academic centers,
inclusion criteria for a traumatic brain injury study involving armed services personnel
would be relatively straightforward. Post- acute, and rehabilitation, care provided to
soldiers by the military could be more centralized which would significantly aid in data
collection and patient stratification. The significance of focusing on soldiers returning
from combat deployment is readily apparent: they suffer the worst injuries/TBIs (with the
possible exception of athletes in contact and combat sports), have the most difficult to
diagnose and triage combination of symptoms, and exhibit the poorest outcomes.
Additionally, links and potential cross pollination with PTSD and the societal impact
have been acknowledged and require further study. Well designed and implemented
studies with proper triage, outcome assessments and multidisciplinary approaches will
not only elucidate previously unknown linkages between TBI and various ailments
(PTSD, neuropsychiatric dysregulation etc.) but facilitate applicable conclusions and
treatments to the general populace and/or other at-risk groups (contact and combat sports
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participants). We are on the cusp of a new age in traumatic brain injury research and
treatment and we believe that an exo-proteomic approach to the study of this disease is
vital to the discovery of its cure and treatment.
It is also vitally important to be aware of the potential for unforeseen impact as
the efficacy of TBI assessment improves. While the benefits of injury treatment, and
especially prevention, are self-evident, there are potential pitfalls with implementation of
protocols designed to minimize risk. With the increased awareness of the dangers of
concussion in the pediatric population, enrollment in youth football and other contact
sports is declining precipitously. Armed services personnel experience a wide array of
injuries while performing tasks essential to their duties. Links between TBI and PTSD are
suspected and perhaps even probable. Yet the mechanistic underpinnings of how exactly
the dysregulation caused by concussive events leads to the behaviors observed in posttraumatic stress have yet to be elucidated. Discovery of a panel of definitive trauma
specific biomarkers could, and would, lead to a fuller understanding of etiology and
progression. However, great care must be taken in how to utilize our burgeoning
knowledge. Removal from participation in contact sports based upon a likelihood of
injury could be problematic. Determinations of ineligibility for enlistment in the armed
services or imposed limitations in scope of service or in specific roles that result from
preemptive testing could have profound negative effects on the culture of service and
sacrifice inherent in our military. The cost in manpower and personnel have the potential
to be significant. Therefore, we must tread carefully in how we utilize and implement the
knowledge that we acquire through the advancements in our methodologies.
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